Press release
Ulcerative Colitis Pipeline Insights Report | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook [https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Ulcerative Colitis Pipeline Report
* In January 2025:- Eli Lilly and Company: - The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC). The study will last approximately 4-5 years. Screening is required within 35 days prior to enrollment. For each participant, the total duration of the clinical trial will be about 69 weeks including screening.
* In January 2025:- AbbVie:- A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. Participants who do not respond to treatment will receive open-label SC lutikizumab. Participants who complete the Week 52 visit and in whom therapeutic benefit to study drug is confirmed by the investigator may roll over into an optional, blinded 52-week long-term extension (LTE).
* In January 2025:- Genentech Inc.:- A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
* In January 2025:- Janssen Pharmaceuticals :- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis. The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
* DelveInsight's Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
* The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies , and others.
* Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Ulcerative Colitis Emerging Drugs Profile
* Obefazimod: Abivax
Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.
* ABBV-668: AbbVie
ABBV-668 is under development for the treatment of crohn's disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
* TEV-48574: Teva Pharmaceutical
Anti-TL1A (TEV-'574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-'574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-'574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn's disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-'574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
* SOR102: Sorriso Pharmaceuticals
SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.
Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs [https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Ulcerative Colitis Companies
Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Ulcerative Colitis Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Ulcerative Colitis Pipeline Report
* Coverage- Global
* Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
* Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
* Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
"Stay Ahead in Gastroenterology Research-Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies [https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Ulcerative Colitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ulcerative Colitis- DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Ulcerative Colitis Collaboration Deals
* Late Stage Products (Preregistration)
* Mirikizumab: Eli Lilly and Company
* Drug profiles in the detailed report.....
* Late Stage Products (Phase III)
* Obefazimod: Abivax
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ABBV-668: AbbVie
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* SOR102: Sorriso Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Ulcerative Colitis Key Companies
* Ulcerative Colitis Key Products
* Ulcerative Colitis- Unmet Needs
* Ulcerative Colitis- Market Drivers and Barriers
* Ulcerative Colitis- Future Perspectives and Conclusion
* Ulcerative Colitis Analyst Views
* Ulcerative Colitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ulcerative-colitis-pipeline-insights-report-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/blog/implantable-cardiac-monitors-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ulcerative Colitis Pipeline Insights Report | DelveInsight here
News-ID: 3837731 • Views: …
More Releases from ABNewswire
Analysis of the Toxicity and Safety of Aluminum Foam
Aluminum Foam [https://www.beihaicomposite.com/aluminum-foam-tag/] itself is non-toxic and generally safe in most applications. However, its safety is also influenced by specific usage conditions and environmental factors. As a lightweight porous material, aluminum foam has seen widespread application across various fields in recent years. Due to its uNique physical and chemical properties, aluminum foam performs exceptionally well in sound insulation, thermal insulation, and vibration damping. However, as its application has become more…
Nickel foam: the star material for catalyst carriers
Core Advantages of Nickel Foam [https://www.beihaicomposite.com/foam/] as Catalyst Carrier
1. Three-dimensional Porous Structure
Nickel Foam [https://www.beihaicomposite.com/nickel-foam/] has a high porosity of more than 95% and a pore size range of typically 100-500 microns, which significantly increases the loading area of the catalyst. For example, in the electrolysis of water reaction, the nickel foam carrier can enhance the distribution density of the active substance by 3-5 times, effectively reducing the local current density.
2.…
Aluminum Foam: Opening a New Vision for Building Decoration
Aluminum Foam [https://www.beihaicomposite.com/foam/], as the name suggests, is an aluminum material with a uniform pore structure all over its interior. This unique structure gives it amazingly lightweight properties, reducing its weight dramatically compared to traditional metal sheets. For architectural decoration, this means that a designer's vision is no longer bound by gravity. Whether it's shaping an undulating wall like a dune or creating a ceiling that looks like a floating…
Innovative applications of copper foam in the field of water treatment
Product: Copper foam sheet [https://www.beihaicomposite.com/functional-characteristics-of-ultra-thick-copper-foam-product/]
Size: 240x120x10mm
Usage: Water Treatment [https://www.beihaicomposite.com/water-treatment/]
Ship to: Sweden
As a new type of porous functional Material, copper foam is showing broad application prospects in the field of water treatment due to its uNique physicochemical properties. This metal material with a three-dimensional connected pore structure, combined with high specific surface area, excellent electrical conductivity, and antibacterial properties, provides an innovative solution to the bottleneck of traditional water treatment technology.
Core…
More Releases for Ulcerative
Novel Therapies for Ulcerative Colitis Patients
"The Business Research Company recently released a comprehensive report on the Global Ulcerative Colitis Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The ulcerative colitis market size…
Ulcerative Colitis Market - Breaking Barriers, Transforming Digestive Health: Ul …
Newark, New Castle, USA: The "Ulcerative Colitis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Ulcerative Colitis Market: https://www.growthplusreports.com/report/ulcerative-colitis-market/8815
This latest report researches the industry structure, sales, revenue,…
Ulcerative Colitis Market - Breaking Barriers, Empowering Resilience: Transformi …
Newark, New Castle, USA - new report, titled Ulcerative Colitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Ulcerative Colitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Ulcerative Colitis market. The report offers an overview of the market, which…
Ulcerative Colitis - Drug Pipeline Landscape, 2023
Global Ulcerative Colitis Market report from Global Insight Services is the single authoritative source of intelligence on ulcerative colitis market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Ulcerative Colitis Market
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained…
Ulcerative Colitis Pipeline Analysis, 2016
Ulcerative colitis is an inflammatory condition of colon, in which ulcer is formed in the colon lining. In ulcerative colitis, inflamed colon develops small number of open lesion, that produce pus and mucous. The abnormal response of the immune system causes inflammation in the colon.
The ulcerative colitis pipeline has more than 45 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is…
